title: [New drug treatment for age-related macular degeneration].
abstract: New drugs for age-related macular degeneration present a major advance in the treatment of the most common cause of blindness in Iceland. Vascular endothelial growth factor antibodies reduce the risk of blindness and improve vision in patients with age-related macular degeneration.
authors: Laeknalid Háskóla Islands. einarste@landspitali.is
authors: Einar
authors: E
authors: Stefánsson
authors: Morten
authors: M
authors: la Cour
authors: Gudleif
authors: G
authors: Helgadóttir
authors: Haraldur
authors: H
authors: Sigurdsson
authors: Fridbert
authors: F
authors: Jónasson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007267:Injections / Q000379:methods; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab